Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
yes july 28 is correct but unconfirmed. official date has not
been posted
*T2 Biosystems shares are trading higher after Canaccord Genuity maintained a Buy rating on the stock and raised its price target from $3 to $4
T2 Biosystems Is Maintained at Buy by Canaccord Genuity
T2 Bioystems Says On Jul. 1 Co. Submitted EUA Request To FDA For T2SARS-CoV-2 Panel
8:05 am ET July 14, 2020 (Benzinga)
On June30, 2020, T2 Bioystems, Inc. (the “Company”) announced the US launch of its COVID-19 molecular diagnostic test, the T2SARS-CoV-2 Panel, after validation of the test meeting the United States Food and Drug Administration’s (FDA’s) requirements for an Emergency Use Authorization (EUA). On July1, 2020, the Company submitted an EUA request to the FDA for the T2SARS-CoV-2 Panel.
T2 Biosystems, Inc. (NASDAQ: TTOO) rose 8.7% to $1.50 in pre-market trading.
T2 Biosystems Solidifies Its Position as a COVID-19 Stock With New Test
Chris Lange 7/1/2020
US Covid-19 cases are climbing but some state and local leaders are clashing over moves to curb the spread
Libya’s Oil Industry Thrown Into More Chaos as Haftar Digs In
24/7 Wall St. logoT2 Biosystems Solidifies Its Position as a COVID-19 Stock With New Test
T2 Biosystems Inc. (NASDAQ: TTOO) solidified its position as a coronavirus stock on Wednesday morning when it announced the launch of its COVID-19 molecular diagnostic test. Coronavirus testing has become a very lucrative field, with a few companies capitalizing on the significant demand for testing globally.
Specifically, the company announced the completion of validation of its COVID-19 molecular diagnostic test, the T2SARS-CoV-2 Panel. The test was developed by T2 Biosystems under a license agreement with the Center of Discovery and Innovation at Hackensack Meridian Health and is being commercially distributed after validation meeting requirements for an Emergency Use Authorization (EUA) request to FDA.
Shares of T2 Biosystems Inc (NASDAQ:TTOO) have earned an average recommendation of “Buy” from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $1.83.
TTOO has been the topic of several research reports. ValuEngine upgraded T2 Biosystems from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. Zacks Investment Research raised shares of T2 Biosystems from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a report on Saturday, May 9th. Finally, SVB Leerink restated an “outperform” rating and issued a $2.00 price target (down from $5.00) on shares of T2 Biosystems in a research report on Wednesday, May 6th.
tell me when it gets to $5.00 then I MAY consider selling part of
my position. maybe 25%
I am very long this stock and view it as a diamond in the rough.
these pennies invested are worth millions of dollars.
yes up is the trend. earnings are expected To be reported July 28
PATIENCE is the name of the game. Those that are very long like me
will be rewarded beyond ones dream. do not sell short and miss the
big gains.
stems (TTOO) Stock Moves -0.75%: What You Should Know
4:50 pm ET July 7, 2020 (Zacks)
In the latest trading session, T2 Biosystems (TTOO) closed at $1.33, marking a -0.75% move from the previous day. This change was narrower than the S&P 500's daily loss of 1.08%. Elsewhere, the Dow lost 1.51%, while the tech-heavy Nasdaq lost 0.86%.
Coming into today, shares of the diagnostics company had 0% in the past month. In that same time, the Medical sector lost 0.35%, while the S&P 500 lost 0.3%.
TTOO will be looking to display strength as it nears its next earnings release. In that report, analysts expect TTOO to post earnings of -$0.18 per share. This would mark year-over-year growth of 48.57%.
Investors should also note any recent changes to analyst estimates for TTOO. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. TTOO currently has a Zacks Rank of #3 (Hold).
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 151, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Joecanada13---I agree with you. Patience is the only word that fits
the market. a very intelligent word of wisdom.
lower volume today. must be vacation time. shorts have gone to sleep.
This is only the beginning
TTOO News: T2 Biosystems Announces U.S. Launch of COVID-19 Diagnostic Test
hang on to your shares-------dont give them away
key word is launch its got a long way to go
The lightweight news deflated the balloon. News needs to have more
meat on the bone. I am sure new board members are working on higher sales
and increased earnings.
A retrospective study on T2Candida by @HSVHospital concluded that using T2Candida led to fewer days of antifungal therapy and many opportunities for improvement in antifungal #stewardship were identified.' -T2 Biosystems Tweet
Benzinga
mojo joyo ====good for you
I am very long also I think number of test going forward is the
catalyst.
mojo joyo====whats your projection after $2 are cracked???
THIS IS THE CATALYST THAT WILL ROCK THE STOCK UPWARDS
T2 Biosystems Says Anticipates Shipping First SARS-CoV-2 Tests To US customers As Early As End Of June; Estimates Could Potentially Ramp Up To ~1M Tests/Month
a pre market prime is fuel to start lift off. this could be the day.
ress Release: T2 Biosystems Announces Changes to Board of Directors
4:06 pm ET June 15, 2020 (Dow Jones)
T2 Biosystems Announces Changes to Board of Directors
Three new appointments add significant clinical and commercialization experience and expand board diversity
LEXINGTON, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced three new Board of Director appointments. The three new directors will add significant clinical and commercialization experience and expand board diversity, coupled with a strong understanding of the Company's customer base.
The new appointments include: Thierry Bernard, Chief Executive Officer, QIAGEN; Dr. Ninfa Saunders, President and Chief Executive Officer, Navicent Health; and Robin Toft, Founder and Chief Executive Officer, Toft Group, a ZRG company.
"We are thrilled to add to our Board three individuals whose commercial expertise and combined background in molecular diagnostics, clinical care, and life science leadership will bring invaluable perspective and insight to our business, helping us to achieve our goals of accelerating our sales, improving our operations, and advancing our pipeline," said John Sperzel, President and Chief Executive Officer, T2 Biosystems. "Our commitment to developing innovative technology that helps save lives and improve patient outcomes remains steadfast, and adding these three industry leaders will bolster our efforts to accomplish that in the coming months and years."
Thierry Bernard is the CEO at QIAGEN. Mr. Bernard joined QIAGEN in February 2015 to lead QIAGEN's growing presence in molecular diagnostics. Mr. Bernard previously held multiple roles at bioMerieux for fifteen years, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. Prior to joining bioMerieux, he served in management roles in multiple international environments. Mr. Bernard is a member of the Board of Directors of First Light Biosciences. He has earned degrees from Sciences Po (Paris), Harvard Business School, London School of Economics and the College of Europe, and is a member of French Foreign Trade Advisors.
Dr. Ninfa M. Saunders, FACHE, is the President and CEO of Navicent Health, the second largest hospital in Georgia and a tertiary regional teaching medical center. Dr. Saunders has more than 45 years of hospital administrative and clinical experience, and prior to her current role, served as the President and COO of Virtua Health, the largest health system in southern New Jersey. Dr. Saunders was recognized by Modern Healthcare as one of 2019's Top 25 Women Leaders in the U.S. and was twice named one of the "Most Influential Women of the Mid-Market" in the U.S. by CEO Corporation. Dr. Saunders serves on the boards of the Georgia Hospital Association and the American Hospital Association, where she is the past chair for the Institute for Diversity. Dr. Saunders completed her Doctorate in Healthcare Administration at the Medical University of South Carolina, earned a Master's of Business Administration from Emory University, and a Master of Science in Nursing from Rutgers University.
Robin Toft is the founder and CEO of Toft Group, a ZRG company, where she combines a deep inside knowledge of the life science industry with a passion for building game-changing management teams. Ms. Toft has placed hundreds of executives at innovation-led life science companies. A champion of diverse executive teams, she has built a reputation for recruiting women and minorities into C-level and board of director roles. Prior to founding Toft Group in 2010, Ms. Toft served 20+ years as a biotech executive, most recently as Senior Vice President, Commercial Operations at Roche Molecular Diagnostics. In the 2020 American Business Awards, Ms. Toft received three Gold awards for Lifetime Achievement, Maverick of the Year and Woman of the Year. She currently serves on The Clearity Foundation board for ovarian cancer care, and is Chairman of LEAD San Diego, dedicated to developing civically engaged leaders. Ms. Toft earned a Bachelor of Science from Michigan State University.
Along with these additions, the Company announced the departure of three long-standing board members: Michael Cima, Ph.D., Adrian M. Jones, and Stanley Lapidus.
"We are profoundly grateful for the passion, ingenuity and leadership exhibited by the departing board members over the past several years," said John McDonough, Chairman of the Board of Directors, T2 Biosystems. "Their collective contributions have made a significant and lasting impact on the Company, for which we will remain forever grateful."
The new board members will join the following existing board members:
-- John Sperzel, President and CEO, T2 Biosystems
-- John McDonough, Chairman of the Board, T2 Biosystems
-- John W. Cumming, Former Chairman and CEO, Hologic
-- David Elsbree, Former Senior Partner, Deloitte & Touche
-- Seymour Liebman, Executive Vice President, Chief Administrative Officer
and General Counsel of Canon U.S.A, Inc.; Senior Managing Executive
Officer of Canon Inc., Japan; and Vice Chairman, Canon Solutions America,
Inc.
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems' products include the T2Dx(R) Instrument, T2Candida(R) Panel, the T2Bacteria(R) Panel, and the T2Resistance(TM) Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR(R) ) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris(TM) Panel, T2SARS-CoV-2(TM) Panel, and T2Lyme(TM) Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, as well as biothreat pathogens.
Has T2 Biosystems (TTOO) Outpaced Other Medical Stocks This Year?
More
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has T2 Biosystems (TTOO) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
T2 Biosystems is one of 888 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. TTOO is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for TTOO's full-year earnings has moved 28.71% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, TTOO has gained about 0.85% so far this year. At the same time, Medical stocks have lost an average of 1.41%. As we can see, T2 Biosystems is performing better than its sector in the calendar year.
To break things down more, TTOO belongs to the Medical - Instruments industry, a group that includes 94 individual companies and currently sits at #83 in the Zacks Industry Rank. On average, this group has lost an average of 3.91% so far this year, meaning that TTOO is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track TTOO. The stock will be looking to continue its solid performance.
What a difference a day makes. pre market leaning toward the upside.
No Problem. it will slide thru $1.5o like crap thru a goose.
there is too much momentum to slow train this early.
virus 19 is going to be around for a long time unfortunately.
This is huge
t2Biosystems Says Anticipates Shipping First SARS-CoV-2 Tests To US customers As Early As End Of June; Estimates Could Potentially Ramp Up To ~1M Tests/Month
8:09 am ET May 22, 2020 (Benzinga)
As previously disclosed, T2 Biosystems, Inc. (the “Company”) is currently developing a SARS-CoV-2 test, (the “T2SARS-CoV-2 Test”), to run on the Company’s proprietary T2Dx Instrument platform and anticipates shipping the first tests to U.S. customers for clinical use as early as the end of June. The T2SARS-CoV-2 Test is anticipated to be a sample-to-answer test of a nasopharyngeal swab specimen, with a turnaround time of less than two hours and a limit of detection of less than 1,000 genomic equivalents per milliliter. Based on significant interest regarding the availability of the T2SARS-CoV-2 Test the Company has received to date, the Company anticipates that there will be demand for the test upon it being made commercially available for clinical use. The Company currently has the resources to manufacture up to 100,000 tests per month and, subject to the success of the Company’s efforts to secure additional non-dilutive funding to support expansion of manufacturing capacity, estimates that it could potentially ramp to approximately 1,000,000 tests per month.
its just broken $1.39 and heading north. hang on and watch it fly upwards.
I hope whoever forecasted $4 to $5 by end of June is correct.
That will be quite a run!!!!!!
Has T2 Biosystems (TTOO) Outpaced Other Medical Stocks This Year?
CONTRIBUTOR
Zacks Equity Research Zacks
PUBLISHED
JUN 5, 2020 11:30AM EDT
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has T2 Biosystems (TTOO) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
T2 Biosystems is one of 888 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. TTOO is currently sporting a Zacks Rank of #1 (Strong Buy).
Dont sell your stock*Dont put on stop loss on this one. ok if it gets to
$10 then consider, posters think this one is going to run---so do I
virus 19 has made this opportunity to make lots of money on ttoo.
I have really loaded up at $1.16. I never suggest people to buy stocks.
use your on judgement. see you on Monday. GLTA
9 HOURS AGO
MARKETS
Has T2 Biosystems (TTOO) Outpaced Other Medical Stocks This Year?
CONTRIBUTOR
Zacks Equity Research Zacks
PUBLISHED
JUN 5, 2020 11:30AM EDT
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has T2 Biosystems (TTOO) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
T2 Biosystems is one of 888 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. TTOO is currently sporting a Zacks Rank of #1 (Strong Buy).
I picked up a lot of shares at $1.16. guess some one was trying
to protect pennies and lost their position...good for me.
most all posters think there is lots of up side here. well
I agree with them.
What a way to end the week!!!!!!! next week should be even more
interesting. its all up to ttoo.
*T2 Biosystems shares are trading higher after the company tweeted a report by American Thoracic which states the company's panels enable physicians to target therapy within 3-5 hours of first blood draw, often before 2nd dose of ABX.
Benzinga
OrganiGram Holdings Inc Is Maintained at Outperform by Raymond James
Dow Jones
StevenRisk previous post 10039 was for you
The purchase is in your favor. Hang in there . this is a very up and
down stock. your timing is going to be ok.
have fun and watch it grow.
Organigram Successfully Completes Amendment to Credit Facilities with Bank of Montreal
6:00 am ET May 29, 2020
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (collectively, the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce that the Company has amended its credit agreement dated May 31, 2019, with Bank of Montreal ("BMO") as lead arranger and agent as well as a syndicate including three other lenders (the "Credit Agreement Amendment"). The Credit Agreement Amendment modifies certain terms of the $115 million term loan (the "Term Loan") and $25 million revolving credit facility (the "Revolver", and together with the Term Loan, the "Facilities").
The Credit Agreement Amendment: (i) extends the final draw deadline of the Term Loan to July 31, 2020; (ii) postpones the commencement of principal repayments on the Term Loan to November 30, 2020; (iii) adjusts certain financial ratios to be maintained by the Company both before and after November 30, 2021 (the "Conversion Date"); (iv) modifies the applicable margin pricing and standby fee terms to reflect current market conditions; and (v) removes the uncommitted option to increase the Facilities by an incremental $35 million.
As at the date hereof, Organigram has drawn $85 million of the Term Loan and pursuant to the agreed upon terms and conditions of the Facilities can continue to draw down up to $30 million through to July 31, 2020. Principal repayments on the Term Loan will commence on November 30, 2020 at a rate of 2.5% per quarter. The Revolver for general corporate and working capital purposes is available based on a percentage of trade receivables and is undrawn as at the date of this press release. The Company may, at its discretion, repay the balance of the Facilities without penalty, at any time. Subject to certain exceptions, funds raised by the Company after December 31, 2020 are required to be used to repay the Facilities.
The pricing of the Facilities continues to be a set margin, which before the Conversion Date will be fixed at 2.5% or 3.75%, over BMO's Prime Based Loans or a Bankers' Acceptance or equivalent rate based on the applicable term, respectively. After the Conversion Date, the margin may increase or decrease based on a pricing grid linked to the Company's senior funded debt to EBITDA ratio as calculated at each quarter-end. Based on the current Bankers' Acceptance benchmark rates and the margin in the pricing grid, the interest payable is expected to be in the range of 4.4% to 4.8% per annum.
In addition to the existing customary financial and restrictive covenants, the Company has agreed as part of the Amendment, to maintain an unrestricted cash balance of not less than $30 million at all times, $8 million of which has been deposited as cash collateral with BMO as security for the Facilities. The Facilities continue to be secured by the assets of Organigram, which primarily consist of the Company's Moncton campus production facility.
The disclosure in this news release relating to the Credit Agreement and the Amendment is qualified in its entirety by the full text of such documents, copies of which are or will be filed on www.sedar.com and www.sec.gov.
About Organigram Holdings Inc.
Organigram Holdings Inc. is a NASDAQ Global Select and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.
Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company's global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, Trailer Park Buds, Ankr Organics and Trailblazer. Organigram's facility is located in Moncton, New Brunswick and the Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).
WHeeeeeee NICE RIDE. HOPE YOU ENJOY IT
Organigram Rolls out Cannabis 2.0 Products to Medical Consumers
10:48 am ET May 28, 2020 (BusinessWire)
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce that as of May 19th, 2020, the Company has extended its medical cannabis offering to include products from its cannabis 2.0 adult-use recreational portfolio.
Products now available to medical cannabis consumers include ready-to-use Edison Cannabis Company (Edison) vape pens powered by Feather; Edison-branded pods specifically for PAX Era vaporizers; and Edison Bytes chocolates in dark and milk chocolate, in both one and two pack formats.
"Organigram has a deep and long-standing commitment to our medical cannabis consumers," says Greg Engel, CEO, Organigram. "As more and more patients turn their attention to new forms of cannabis, we are proud to offer them access to an innovative and growing product portfolio."
Earlier this year, Organigram announced its first shipments of Edison vape pens, pods and cannabis-infused chocolate to retailers across Canada. This follows the Company's $15 million investment in a high-speed, high-capacity, fully automated chocolate manufacturing line.
"We are continuously innovating, responding to the feedback from customers and building brands that we believe reflect their evolving needs and preferences. Initial feedback from our medical consumers has been very positive and we look forward to continuing to share new products with patients across the country," says Engel.
Feedback from the Company's medical cannabis customers will continue to help inform product development strategies for medical consumers moving forward.
Certain of the Company's cannabis 2.0 products are expected to be available in the near future through Medical Cannabis by Shoppers, the online medical cannabis platform of Shoppers Drug Mart Inc. (Shoppers) in accordance with the terms of the Company's supply agreement with Shoppers.
About Organigram Holdings Inc.
Organigram Holdings Inc. is a NASDAQ Global Select and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.
Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company's global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, Trailer Park Buds, Ankr Organics and Trailblazer. Organigram's facility is located in Moncton, New Brunswick and the Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc., a leading licensed producer of cannabis, announced earlier this year that the Company had received Health Canada's approval for the licensing of the remainder of its Phase 5 expansion together with the renewal of its licenses for standard cultivation, standard processing and sale for medical purposes under the Cannabis Regulations. The renewed and expanded licenses are effective as of March 20th, 2020. The terms of the licenses include approval of a two-floor production facility designed to support all processing activity as well as dedicated spaces for packaging of flower, pre-rolls, vape pens and powdered beverages. The Phase 5 expansion also includes a new extraction facility with increased capacity for CO2 extraction, and winterization as well as new capabilities designed for future product development.